Busulfan versus hydroxyurea in long-term therapy of chronic myelogenous leukemia
- PMID: 6956430
- DOI: 10.1002/1097-0142(19821101)50:9<1683::aid-cncr2820500904>3.0.co;2-x
Busulfan versus hydroxyurea in long-term therapy of chronic myelogenous leukemia
Abstract
Survival of patients with chronic myeloid leukemia seen in the University of Colorado Leukemia Clinic were reviewed with respect to therapy. A total of 55 patients seen consecutively through mid 1980 were included in this study. Of these patients 30 were treated with busulfan, 14 were treated with hydroxyurea and 11 received under modalities. Busulfan treated patients who are now deceased, have had a median survival of 35 months (range, 13-108) and actuarial analysis shows the total busulfan treated population to have an expected median survival of 48 months. Hydroxyurea treated patients who are still alive have been followed for a median period of 69 months (range, 25-136 months) and a projected median survival for periods of 56 and 90 months, respectively. These data suggest that hydroxyurea may be an important treatment modality in the treatment of chronic myelogeous leukemia.
Similar articles
-
Randomized study on the treatment of chronic myeloid leukemia (CML) in chronic phase with busulfan versus hydroxyurea versus interferon-alpha.Blut. 1988 Feb;56(2):87-91. doi: 10.1007/BF00633471. Blut. 1988. PMID: 3277680 Clinical Trial.
-
Hydroxyurea versus busulfan in the treatment of chronic myelogenous leukemia.Am J Clin Oncol. 1982 Jun;5(3):307-13. doi: 10.1097/00000421-198206000-00013. Am J Clin Oncol. 1982. PMID: 6952759
-
Combined plateletpheresis and cytotoxic chemotherapy for symptomatic thrombocytosis in myeloproliferative disorders.Cancer. 1993 Aug 15;72(4):1209-18. doi: 10.1002/1097-0142(19930815)72:4<1209::aid-cncr2820720413>3.0.co;2-4. Cancer. 1993. PMID: 8339212
-
Chemotherapy of chronic myelocytic leukemia.Semin Hematol. 1969 Oct;6(4):323-43. Semin Hematol. 1969. PMID: 4900650 Review. No abstract available.
-
Treatment choices in chronic myelogenous leukemia.Hosp Pract (Off Ed). 1992 Sep 30;27(9A):95-8, 101. Hosp Pract (Off Ed). 1992. PMID: 1522171 Review. No abstract available.
Cited by
-
Randomized study on the treatment of chronic myeloid leukemia (CML) in chronic phase with busulfan versus hydroxyurea versus interferon-alpha.Blut. 1988 Feb;56(2):87-91. doi: 10.1007/BF00633471. Blut. 1988. PMID: 3277680 Clinical Trial.
-
The Bcr-Abl tyrosine kinase inhibitor imatinib and promising new agents against Philadelphia chromosome-positive leukemias.Int J Clin Oncol. 2007 Oct;12(5):327-40. doi: 10.1007/s10147-007-0699-1. Epub 2007 Oct 22. Int J Clin Oncol. 2007. PMID: 17929114 Review.
-
Chronic myelogenous leukemia--recent advances in treatment and pathogenesis.West J Med. 1986 Mar;144(3):338-43. West J Med. 1986. PMID: 3457494 Free PMC article. No abstract available.
-
Nitric oxide generation from hydroxyurea via copper-catalyzed peroxidation and implications for pharmacological actions of hydroxyurea.Jpn J Cancer Res. 1997 Dec;88(12):1199-204. doi: 10.1111/j.1349-7006.1997.tb00349.x. Jpn J Cancer Res. 1997. PMID: 9473738 Free PMC article.
-
Success story of targeted therapy in chronic myeloid leukemia: a population-based study of patients diagnosed in Sweden from 1973 to 2008.J Clin Oncol. 2011 Jun 20;29(18):2514-20. doi: 10.1200/JCO.2011.34.7146. Epub 2011 May 16. J Clin Oncol. 2011. PMID: 21576640 Free PMC article.